Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by Mole101on Jun 09, 2021 12:32pm
144 Views
Post# 33355482

Research Ethics Board: About the Health Canada ..

Research Ethics Board: About the Health Canada ..

If we need to apply to HC for serology test approval, this maybe the process:


Research Ethics Board: About the Health Canada and Public Health Agency of Canada REB

 
2021 meeting dates
Meeting dates Submission deadlines
January 21, 2021 December 31, 2020
February 18, 2021 January 28, 2021
March 18, 2021 February 25, 2021
April 15, 2021 March 25, 2021
May 13, 2021 April 22, 2021
June 10-11, 2021 May 20, 2021
July 15, 2021 June 24, 2021 
August 2021 No meeting
September 9, 2021 August 19, 2021 
October 7, 2021 September 16, 2021 
November 4, 2021 October 14, 2021 
December 9, 2021 November 18, 2021

Research involving humans can greatly benefit human society, but it must be done in a way that protects and respects the research participants. The Health Canada and Public Health Agency of Canada (PHAC) Research Ethics Board (REB) was created to provide this oversight. It reviews all research from Health Canada and PHAC that involves humans (including living individuals, human biological materials and information from or about humans) to ensure that it meets the highest ethical standards, and that the greatest protection is provided to research participants. Specifically, the Health Canada-PHAC REB reviews all research involving humans that is:

  • Carried out by Health Canada or PHAC (intramural);
  • Performed by Health Canada or PHAC in collaboration with external researchers;
  • Carried out on Health Canada or PHAC premises; or
  • Conducted under contract to Health Canada or PHAC.

The REB may also review research that is funded by Health Canada or PHAC through grants and contributions to external researchers who do not have access to another research ethics board.

Researchers must obtain ethics approval in writing before the research begins.

All research is also subject to continuing ethics review by the REB throughout the life of the project. To maintain a valid ethics certificate, applicants are required to submit annual reports to the REB, seek approval for amendments to the research protocol, and report any unanticipated issues or events.

The REB is guided by the principles of the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans, which sets the standard for research ethics boards in Canada.

https://www.canada.ca/en/health-canada/services/science-research/science-advice-decision-making/research-ethics-board/apply-ethics-review.html

<< Previous
Bullboard Posts
Next >>